Retinal ischemia
diseaseOn this page
Also known as ischaemic disease of retinaischemic disease of retinaretina ischaemic diseaseretina ischemic disease
Summary
Retinal ischemia (MONDO:0001538) is a disease with 1 GWAS associations across 1 studies and 9 clinical trials. Top therapeutic interventions include fluorescein. A subtype of ischemic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | retinal ischemia |
| Mondo ID | MONDO:0001538 |
| DOID | DOID:12510 |
| ICD-10-CM | H35.82 |
| SNOMED CT | 26468004 |
| UMLS | C0162291 |
| MedGen | 102372 |
| Anatomy (UBERON) | UBERON:0000966 |
| Is cancer (heuristic) | no |
Also known as: ischaemic disease of retina · ischemic disease of retina · retina ischaemic disease · retina ischemic disease
Data availability: 1 GWAS association (1 study).
Disease family
This is a subtype of ischemic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › ischemic disease › retinal ischemia
Related subtypes (5): limb ischemia, brain ischemia, ischemic bowel disorder, myocardial ischemia, peripheral ischemia
Genetics & variants
GWAS landscape
1 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs74339173 | 9e-08 | Metazoa_SRP - ADTRP | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90651827 | Liu TY | 2025 | 817 | 219,284 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs74339173 | 6 | 11672385 | G>A | 0.05 | intron_variant | Metazoa_SRP - ADTRP | 9e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE4 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03730779 | PHASE4 | WITHDRAWN | Oxygen Therapy for Retinal Ischemia |
| NCT04038125 | PHASE4 | UNKNOWN | Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME |
| NCT00841373 | PHASE1/PHASE2 | COMPLETED | Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease |
| NCT06431711 | Not specified | RECRUITING | Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease |
| NCT06500728 | Not specified | RECRUITING | Visual Involvement in Giant Cell Arteritis |
| NCT07420374 | Not specified | RECRUITING | Ambulatory Stroke Unit Treatment for Elderly Patients |
| NCT03061526 | Not specified | UNKNOWN | Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion |
| NCT03422965 | Not specified | UNKNOWN | Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus |
| NCT03906383 | Not specified | COMPLETED | Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUORESCEIN | 4 | 1 |
| CHEMBL177756 | 0 | 1 |
Related Atlas pages
- Drugs: Fluorescein